ABSTRACT
The non-essential amino acids serine, glycine, and alanine, as well as diverse sphingolipid species, are implicated in inherited neuro-retinal disorders and are metabolically linked by serine palmitoyltransferase (SPT), a key enzyme in membrane lipid biogenesis. To gain insights into the pathophysiological mechanisms linking these pathways to neuro-retinal diseases we performed a targeted metabolomic analysis of these pathways in sera from patients diagnosed with two metabolically intertwined diseases: macular telangiectasia type II (MacTel), hereditary sensory autonomic neuropathy type 1 (HSAN1), or both. In a cohort of >350 participants, MacTel patients exhibited broad alterations of amino acids, including changes in serine, glycine, alanine, glutamate, and branched-chain amino acids reminiscent of diabetes. MacTel patients had elevated 1-deoxysphingolipids but reduced levels of complex sphingolipids in circulation. A mouse model indicates this depletion in complex sphingolipids can be driven by low dietary serine and glycine. HSAN1 patients exhibited elevated serine, lower alanine, and a reduction in canonical ceramides and sphingomyelins compared to controls. Those patients diagnosed with both HSAN1 and MacTel showed the most significant decrease in circulating sphingomyelins. These results highlight metabolic distinctions between these two diseases, emphasize the importance of membrane lipids in the progression of MacTel, and suggest distinct therapeutic approaches.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
We thank the Lowy family for their support of the MacTel Project, the Lowy Medical Research Institute. M.B. was supported by an Australian National Health and Medical Research Council (NHMRC) Investigator Grant (GNT 1195236). B.R.E.A. was supported by a NHMRC Early Career Fellowship (GNT 1157776). This work was also supported by the Victorian Government's Operational Infrastructure Support Program and the NHMRC Independent Research Institute Infrastructure Support Scheme (IRIISS) and by an unrestricted departmental grant from Research to Prevent Blindness to the Moran Eye Center of the University of Utah. This work was also supported by NIH grant R01CA234245 and NSF CAREER Award #1454425 (to C.M.M.).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The MacTel Project consortium recruited cases and controls at participating clinical centers in four countries (Australia, Germany, UK, and US). Informed written consent was obtained in accordance with ethics protocols for human subjects approved by the appropriate governing body at each site in accordance with the Declaration of Helsinki. Protocols and records of consent were centrally managed by the EMMES Corporation. The following ethics boards granted approval for human subject enrollment: Moorfields Eye Hospital, London, UK: National Research Ethics Service Save Sight Institute, Sydney, Australia: South Eastern Sydney Illawarra Area Health Service Human Research Ethics Committee-Northern Hospital Network Scripps Research Institute, La Jolla, California, USA: Scripps Institutional Review Board University of Bonn, Bonn, Germany: Rheinische Friedrich-Wilhelms-Universitaet Ethik-Kommission John Moran Eye University of Utah, Salt Lake City, Utah, USA: The University of Utah Institutional Review Board Centre for Eye Research, Victoria, Australia: The Royal Victorian Eye and Ear Hospital
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
